Get the Stockscreener App
693.54
2.99%
-21.38
After Hours:
693.54
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Mckesson Corporation stock is traded at $693.54, with a volume of 1.15M.
It is down -2.99% in the last 24 hours and down -5.35% over the past month.
McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
See More
Previous Close:
$714.92
Open:
$711.19
24h Volume:
1.15M
Relative Volume:
1.43
Market Cap:
$86.63B
Revenue:
$359.05B
Net Income/Loss:
$3.30B
P/E Ratio:
26.85
EPS:
25.83
Net Cash Flow:
$5.23B
1W Performance:
-2.34%
1M Performance:
-5.35%
6M Performance:
+16.61%
1Y Performance:
+12.40%
1-Day Range:
$686.30
$717.00
1-Week Range:
$686.30
$717.00
52-Week Range:
$464.42
$737.89
Mckesson Corporation Stock (MCK) Company Profile
Name
Mckesson Corporation
Sector
Industry
Phone
972-446-4800
Address
6555 STATE HIGHWAY 161, IRVING, TX
Compare MCK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCK
Mckesson Corporation
|
693.54 | 89.30B | 359.05B | 3.30B | 5.23B | 25.83 |
|
COR
Cencora Inc
|
286.08 | 56.56B | 310.23B | 1.69B | 3.58B | 8.62 |
|
CAH
Cardinal Health Inc
|
155.22 | 37.69B | 222.29B | 1.56B | 2.44B | 6.41 |
|
HSIC
Henry Schein Inc
|
67.65 | 8.70B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.699 | 662.04M | 2.22M | -5.63M | -1.68M | -0.24 |
Mckesson Corporation Stock (MCK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Resumed | Mizuho | Neutral |
| Nov-07-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-05-24 | Reiterated | Leerink Partners | Outperform |
| Aug-08-24 | Reiterated | Mizuho | Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| Jul-06-22 | Downgrade | Argus | Buy → Hold |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Feb-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-02-21 | Reiterated | Barclays | Overweight |
| Nov-02-21 | Reiterated | BofA Securities | Buy |
| Nov-02-21 | Reiterated | Evercore ISI | Outperform |
| Nov-02-21 | Reiterated | Jefferies | Buy |
| Mar-30-21 | Upgrade | Argus | Hold → Buy |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-04-20 | Upgrade | Deutsche Bank | Hold → Buy |
| May-22-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-18-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-13-20 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-10-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-05-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jul-22-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Oct-26-18 | Reiterated | Barclays | Equal Weight |
| Jul-20-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-29-18 | Reiterated | Leerink Partners | Mkt Perform |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-02-18 | Reiterated | Mizuho | Neutral |
| Jan-24-18 | Upgrade | Jefferies | Hold → Buy |
View All
Mckesson Corporation Stock (MCK) Latest News
Why McKesson (MCK) Dipped More Than Broader Market Today - Yahoo Finance
3 Reasons Why Growth Investors Shouldn't Overlook McKesson (MCK) - MSN
Albany International Taps Boeing Finance Veteran Willard Station as CFO to Drive Growth Strategy - Stock Titan
Coffee + Connection with Arielle Fisher - McKesson
Daily Dividend Report: William, Cintas, Hershey, McKesson, AWK - Forbes
McKesson (MCK) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Press Release: McKesson Corporation Raises Quarterly Dividend by 15% to $0.82 Per Share - 富途牛牛
McKesson raises quarterly dividend by 15.5% to $0.82/share - MSN
McKesson Corporation Raises Quarterly Dividend by 15% to $0.82 Per Share - Yahoo Finance
McKesson’s Strategic Positioning and Growth Potential: Buy Rating with $800 Price Objective - TipRanks
Are Medical Stocks Lagging McKesson (MCK) This Year? - Yahoo Finance
Wall Street Bulls Look Optimistic About McKesson (MCK): Should You Buy? - Yahoo Finance
McKesson (MCK): Company Profile, Stock Price, News, Rankings - Fortune
McKesson Corporation Stock (MCK) Opinions on Recent Financial Performance and Spinoff Plans - Quiver Quantitative
Is it the right time to buy McKesson Corporation stockUnlock daily stock market insights for success - jammulinksnews.com
What are the latest earnings results for McKesson CorporationAchieve rapid capital gains with smart investing - jammulinksnews.com
Cell and Gene Therapy Third-Party Logistics Market Forecast - GlobeNewswire
Cell and Gene Therapy Third-Party Logistics Market Forecast and Company Analysis Report 2025-2033 Featuring Cencora, Cardinal Health, McKesson, EVERSANA, Knipper Health, Arvato, DHL, and Kuehne+Nagel - Yahoo Finance
Thoughts from Our Experts on Building Strength in the Supply Chain - McKesson
How does McKesson Corporation generate profit in a changing economyTrack top-performing stocks in real-time - jammulinksnews.com
What institutional investors are buying McKesson Corporation stockPhenomenal capital gains - jammulinksnews.com
What is McKesson Corporation company’s growth strategyMaximize your portfolio’s growth potential - jammulinksnews.com
Q&A: Expert Discusses Challenges in Business of Pharmacy | McKesson ideaShare - Drug Topics
These 11 companies have left California over the years - Business Insider
Pharmacy Leaders Enhance Culture with Continuous Learning | McKesson ideaShare - Drug Topics
McKesson Defied The Doubters (Including Me) -- And Could Do It Again (NYSE:MCK) - Seeking Alpha
Expert: Leaders Build Comprehensive Pharmacy Strategies | McKesson ideaShare - Drug Topics
Is McKesson Corporation a good long term investmentUnmatched market performance - Autocar Professional
What makes McKesson Corporation stock attractive to long term investorsConsistently superior profits - jammulinksnews.com
Britt Vitalone Joins Align Technology’s Board of Directors - Medical Product Outsourcing
What drives McKesson Corporation stock priceBreakthrough financial growth - Autocar Professional
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It - MSN
What analysts say about McKesson Corporation stockTriple-digit return opportunities - Autocar Professional
McKesson Corporation Stock Analysis and ForecastFree Market Volatility Navigation Tips - jammulinksnews.com
Here's Why McKesson (MCK) is a Strong Value Stock - Yahoo Finance
TAKANOCK NAMES CRAIG MCKESSON CHIEF COMMERCIAL OFFICER TO ACCELERATE GROWTH STRATEGY - Yahoo Finance
McKesson Amplify Reaches All 50 States - McKesson
Pharmacy Automation Market Surges with 10.12% CAGR; AI & Retail Pharmacy Demand Transform Dispensing in 2025 - GlobeNewswire Inc.
Rated R Meaning Nausea Relief Reliefband® Sport Wrist BandMcKesson Rated R Superstar Cope Logo - roarmag.org
Is McKesson (MCK) an Overlooked Dividend Stock in the Pharma Sector for 2025? - MSN
14 Best Pharma Dividend Stocks to Buy in 2025 - Insider Monkey
Q&A: Pharmacist's Voices Help Propel Industry Changes | McKesson ideaShare - Drug Topics
What to Expect From McKesson's Q1 2026 Earnings Report - MSN
Published on: 2025-07-18 12:27:46 - jammulinksnews.com
Lobbying Update: $460,000 of MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS lobbying was just disclosed - Nasdaq
McKesson Disputes Rite Aid Trust's Antitrust Claim Demands - Law360
McKesson Corporation's Q1 2026 Earnings Preview and Stock PerformanceNews and Statistics - IndexBox
What To Expect From McKesson's Q1 2026 Earnings Report - Barchart.com
Mckesson Corporation Stock (MCK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.96%
2.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):